サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1327753

RNA分析/ トランスクリプトミクスの世界市場

RNA Analysis / Transcriptomics
出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 504 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.46円
RNA分析/ トランスクリプトミクスの世界市場
出版日: 2023年08月14日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 504 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

RNA分析/ トランスクリプトミクスの世界市場は2030年までに179億米ドルに達する

変化したCOVID-19後のビジネス環境において、2022年に66億米ドルと予測されたRNA分析/ トランスクリプトミクスの世界市場は、2030年までに179億米ドルの市場規模に改定され、分析期間2022-2030年に13.4%のCAGRで成長すると予測されます。本レポートで分析したセグメントの1つである試薬/消耗品は、CAGR 14.5%を記録し、分析期間終了時には92億米ドルに達すると予測されます。現在進行中のパンデミック後の回復を考慮し、機器セグメントの成長は今後8年間のCAGRを11.8%に修正しました。

米国市場は26億米ドル、中国はCAGR14.4％で成長予測

米国のRNA分析/ トランスクリプトミクス市場は、2022年には26億米ドルになると推定されます。世界第2位の経済大国である中国は、2022年から2030年のCAGR14.4%で、2030年までに16億米ドルの市場規模に達すると予測されています。その他の注目すべき地理的市場としては、日本とカナダがあり、2022年から2030年にかけてそれぞれ11.6%と13.4%の成長が予測されています。欧州では、ドイツがCAGR約13.3%で成長すると予測されています。

調査対象企業の例

  • Agilent Technologies, Inc.
  • Beckman Coulter, Inc.
  • bioMerieux SA
  • Analytik Jena AG
  • Ambry Genetics
  • Advanced Cell Diagnostics, Inc.
  • Bioneer Corporation
  • BioChain Institute, Inc.
  • Akoya Biosciences, Inc.
  • Acobiom
  • ADS Biotec, Inc.
  • BGI Genomics Co Ltd.
  • 10X Genomics
  • Biois Co Ltd
  • Bertin Technologies, Sas

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • 世界のその他の地域

第4章 競合

目次
Product Code: MCP15286

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global RNA Analysis / Transcriptomics Market to Reach $17.9 Billion by 2030

In the changed post COVID-19 business landscape, the global market for RNA Analysis / Transcriptomics estimated at US$6.6 Billion in the year 2022, is projected to reach a revised size of US$17.9 Billion by 2030, growing at a CAGR of 13.4% over the analysis period 2022-2030. Reagents / Consumables, one of the segments analyzed in the report, is projected to record a 14.5% CAGR and reach US$9.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Instruments segment is readjusted to a revised 11.8% CAGR for the next 8-year period.

The U.S. Market is Estimated at $2.6 Billion, While China is Forecast to Grow at 14.4% CAGR

The RNA Analysis / Transcriptomics market in the U.S. is estimated at US$2.6 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 14.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11.6% and 13.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 13.3% CAGR.

Select Competitors (Total 115 Featured) -

  • Agilent Technologies, Inc.
  • Beckman Coulter, Inc.
  • bioMerieux SA
  • Analytik Jena AG
  • Ambry Genetics
  • Advanced Cell Diagnostics, Inc.
  • Bioneer Corporation
  • BioChain Institute, Inc.
  • Akoya Biosciences, Inc.
  • Acobiom
  • ADS Biotec, Inc.
  • BGI Genomics Co Ltd.
  • 10X Genomics
  • Biois Co Ltd
  • Bertin Technologies, Sas

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Impact of COVID-19 Pandemic and Looming Global Recession
    • 2020 Marked as a Year of Disruption & Transformation
    • As the Race between the Virus & Vaccines Intensifies, Where is the World Economy Headed?
    • Pandemic Impact on RNA Analysis/Transcriptomics Market
    • RNA-Oriented Projects Set to Increase
    • Competition
    • RNA Analysis / Transcriptomics - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • What is RNA-Seq Technology?
    • A Prelude to Transcriptomics Technologies
    • Global Market Prospects & Outlook
    • PCR Emerges as the Leading Technology
    • Drug Discovery Segment Poised to Lead the Global Market
    • North America Emerges as the Major Regional Market
    • World Brands
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Trend Towards Personalized Medicine Fuels Market Growth
    • Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019, 2021, 2023 and 2025
    • World Personalized Medicine Market by Region/Country (2021)
    • Drug Ineffectiveness for Select Therapeutic Categories as a Percentage of Patient Population
    • Number of Available Personalized Medicines in the US (2010-2020)
    • Personalized Medicines as % of New FDA Drug Approvals for 2015-2020
    • Transcriptomics Assume Critical Importance amid Growing Prevalence of Chronic Diseases
    • World Diabetes and Population Statistics (2021, 2030 & 2045)
    • World Diabetes Prevalence (2000-2045)
    • Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
    • Global HIV Prevalence: Number of People Living with AIDs (in Million) by Region as of June 2021
    • Burden of Neurological Diseases: Deaths Per 100,000 Population due to Neurological Conditions in Select Countries
    • Transcriptomics Applications in Disease and Diagnostic Profiling
    • Increasing PCR Applications in Biotechnology Sector
    • Progressive Growth of Omics Technologies: Opportunity for RNA Analysis/Transcriptomics Market
    • The Growing Role of Transcriptomics in Oncology
    • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2020
    • Number of New Cancer Cases and Deaths (in Million) by Region for 2020
    • RNA Sequencing Critical for Cancer and Rare Diseases
    • Bulk-Tissue RNA Sequencing and Single-Cell RNA Sequencing for Cardiovascular Research
    • Bulk RNA Sequencing
    • Single-Cell Sequencing
    • Spatial Transcriptomics
    • Single-Cell RNA-seq Technologies Witness Steady Growth
    • The Evolution of scRNA-seq
    • Growth of Long-Read Transcriptome Sequencing
    • scRNA-seq for Autoimmune Inflammatory Rheumatic Diseases
    • SPLiTseq Beneficial for Understanding Cause of Disease
    • Gene Expression Microarray Technology Gains Ground
    • Microfluidics-based Droplet Technologies Demonstrate Growth
    • inDrops Approach Exhibits Growth
    • Spatial Transcriptomics Market Witnesses Significant Growth
    • Spatial Transcriptomic Data Analysis
    • Next Generation Sequencing Offers Increased Accuracy for Transcriptomics Activity
    • Single-cell NGS Witnesses Rapid Growth
    • RNA Sequencing Benefits Fuel Market Prospects
    • Blood Transcriptome Sequencing for Identifying Rare-Disease Genes
    • Rising Focus on Toxicogenomics: Potential for RNA Analysis/Transcriptomics Markets
    • Growing R&D Spending in Pharma and Biotechnology Sectors Presents Opportunities
    • Pharmaceutical R&D Spending Worldwide (USD Billion) for 2015-2025
    • R&D Spending as % of Revenues in Select Leading Pharmaceutical Companies (2020)
    • R&D Spending (in US$ Billion) of Select Leading Biotechnology Companies for 2020
    • Technological Advancements & Innovations Fuel Market Growth
    • Sci-Plex - A New Technique to Profile Gene Expression within Single Cells
    • Introduction of Oxford Nanopore's Innovative Portable Sequencer for Sequencing Long Reads and RNA Molecules Improves Transcriptomic Analysis
    • RNA-Combine, a Toolkit for More Comprehensively Analyzing Transcriptome Data
    • Aging Demographics Present Opportunities for Transcriptomics Technologies
    • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
    • Challenges Facing RNA/Transcriptomics Market
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for RNA Analysis / Transcriptomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 3: World 15-Year Perspective for RNA Analysis / Transcriptomics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Reagents / Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Reagents / Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 6: World 15-Year Perspective for Reagents / Consumables by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 9: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 12: World 15-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 15: World 15-Year Perspective for Software by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2023 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Polymerase Chain Reaction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Polymerase Chain Reaction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 18: World 15-Year Perspective for Polymerase Chain Reaction by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2023 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 21: World 15-Year Perspective for Sequencing by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2023 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Microarrays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Microarrays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 24: World 15-Year Perspective for Microarrays by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2023 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for RNA Interference by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 26: World Historic Review for RNA Interference by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 27: World 15-Year Perspective for RNA Interference by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2023 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 30: World 15-Year Perspective for Drug Discovery by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2023 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Toxicogenomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Toxicogenomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 33: World 15-Year Perspective for Toxicogenomics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2023 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Clinical Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 35: World Historic Review for Clinical Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 36: World 15-Year Perspective for Clinical Diagnostics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2023 & 2030
    • TABLE 37: World Recent Past, Current & Future Analysis for Comparative Transcriptomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 38: World Historic Review for Comparative Transcriptomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 39: World 15-Year Perspective for Comparative Transcriptomics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2023 & 2030
    • TABLE 40: World RNA Analysis / Transcriptomics Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • RNA Analysis / Transcriptomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 43: USA 15-Year Perspective for RNA Analysis / Transcriptomics by Product - Percentage Breakdown of Value Revenues for Reagents / Consumables, Instruments, Services and Software for the Years 2015, 2023 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 46: USA 15-Year Perspective for RNA Analysis / Transcriptomics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference for the Years 2015, 2023 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 49: USA 15-Year Perspective for RNA Analysis / Transcriptomics by Application - Percentage Breakdown of Value Revenues for Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics for the Years 2015, 2023 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for RNA Analysis / Transcriptomics by Product - Percentage Breakdown of Value Revenues for Reagents / Consumables, Instruments, Services and Software for the Years 2015, 2023 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for RNA Analysis / Transcriptomics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference for the Years 2015, 2023 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for RNA Analysis / Transcriptomics by Application - Percentage Breakdown of Value Revenues for Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics for the Years 2015, 2023 & 2030
  • JAPAN
    • TABLE 59: Japan Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for RNA Analysis / Transcriptomics by Product - Percentage Breakdown of Value Revenues for Reagents / Consumables, Instruments, Services and Software for the Years 2015, 2023 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for RNA Analysis / Transcriptomics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference for the Years 2015, 2023 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for RNA Analysis / Transcriptomics by Application - Percentage Breakdown of Value Revenues for Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics for the Years 2015, 2023 & 2030
  • CHINA
    • RNA Analysis / Transcriptomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 69: China Historic Review for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 70: China 15-Year Perspective for RNA Analysis / Transcriptomics by Product - Percentage Breakdown of Value Revenues for Reagents / Consumables, Instruments, Services and Software for the Years 2015, 2023 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 72: China Historic Review for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 73: China 15-Year Perspective for RNA Analysis / Transcriptomics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference for the Years 2015, 2023 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 75: China Historic Review for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 76: China 15-Year Perspective for RNA Analysis / Transcriptomics by Application - Percentage Breakdown of Value Revenues for Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics for the Years 2015, 2023 & 2030
  • EUROPE
    • RNA Analysis / Transcriptomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for RNA Analysis / Transcriptomics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for RNA Analysis / Transcriptomics by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2023 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for RNA Analysis / Transcriptomics by Product - Percentage Breakdown of Value Revenues for Reagents / Consumables, Instruments, Services and Software for the Years 2015, 2023 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for RNA Analysis / Transcriptomics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference for the Years 2015, 2023 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for RNA Analysis / Transcriptomics by Application - Percentage Breakdown of Value Revenues for Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics for the Years 2015, 2023 & 2030
  • FRANCE
    • TABLE 89: France Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 90: France Historic Review for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 91: France 15-Year Perspective for RNA Analysis / Transcriptomics by Product - Percentage Breakdown of Value Revenues for Reagents / Consumables, Instruments, Services and Software for the Years 2015, 2023 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 93: France Historic Review for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 94: France 15-Year Perspective for RNA Analysis / Transcriptomics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference for the Years 2015, 2023 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 96: France Historic Review for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 97: France 15-Year Perspective for RNA Analysis / Transcriptomics by Application - Percentage Breakdown of Value Revenues for Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics for the Years 2015, 2023 & 2030
  • GERMANY
    • TABLE 98: Germany Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for RNA Analysis / Transcriptomics by Product - Percentage Breakdown of Value Revenues for Reagents / Consumables, Instruments, Services and Software for the Years 2015, 2023 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for RNA Analysis / Transcriptomics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference for the Years 2015, 2023 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 106: Germany 15-Year Perspective for RNA Analysis / Transcriptomics by Application - Percentage Breakdown of Value Revenues for Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics for the Years 2015, 2023 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for RNA Analysis / Transcriptomics by Product - Percentage Breakdown of Value Revenues for Reagents / Consumables, Instruments, Services and Software for the Years 2015, 2023 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for RNA Analysis / Transcriptomics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference for the Years 2015, 2023 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 115: Italy 15-Year Perspective for RNA Analysis / Transcriptomics by Application - Percentage Breakdown of Value Revenues for Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics for the Years 2015, 2023 & 2030
  • UNITED KINGDOM
    • TABLE 116: UK Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 118: UK 15-Year Perspective for RNA Analysis / Transcriptomics by Product - Percentage Breakdown of Value Revenues for Reagents / Consumables, Instruments, Services and Software for the Years 2015, 2023 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 121: UK 15-Year Perspective for RNA Analysis / Transcriptomics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference for the Years 2015, 2023 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 124: UK 15-Year Perspective for RNA Analysis / Transcriptomics by Application - Percentage Breakdown of Value Revenues for Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics for the Years 2015, 2023 & 2030
  • REST OF EUROPE
    • TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 126: Rest of Europe Historic Review for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 127: Rest of Europe 15-Year Perspective for RNA Analysis / Transcriptomics by Product - Percentage Breakdown of Value Revenues for Reagents / Consumables, Instruments, Services and Software for the Years 2015, 2023 & 2030
    • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 129: Rest of Europe Historic Review for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 130: Rest of Europe 15-Year Perspective for RNA Analysis / Transcriptomics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference for the Years 2015, 2023 & 2030
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for RNA Analysis / Transcriptomics by Application - Percentage Breakdown of Value Revenues for Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics for the Years 2015, 2023 & 2030
  • ASIA-PACIFIC
    • RNA Analysis / Transcriptomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 135: Asia-Pacific Historic Review for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 136: Asia-Pacific 15-Year Perspective for RNA Analysis / Transcriptomics by Product - Percentage Breakdown of Value Revenues for Reagents / Consumables, Instruments, Services and Software for the Years 2015, 2023 & 2030
    • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 138: Asia-Pacific Historic Review for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 139: Asia-Pacific 15-Year Perspective for RNA Analysis / Transcriptomics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference for the Years 2015, 2023 & 2030
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for RNA Analysis / Transcriptomics by Application - Percentage Breakdown of Value Revenues for Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics for the Years 2015, 2023 & 2030
  • REST OF WORLD
    • TABLE 143: Rest of World Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 144: Rest of World Historic Review for RNA Analysis / Transcriptomics by Product - Reagents / Consumables, Instruments, Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 145: Rest of World 15-Year Perspective for RNA Analysis / Transcriptomics by Product - Percentage Breakdown of Value Revenues for Reagents / Consumables, Instruments, Services and Software for the Years 2015, 2023 & 2030
    • TABLE 146: Rest of World Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 147: Rest of World Historic Review for RNA Analysis / Transcriptomics by Technology - Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 148: Rest of World 15-Year Perspective for RNA Analysis / Transcriptomics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction, Sequencing, Microarrays and RNA Interference for the Years 2015, 2023 & 2030
    • TABLE 149: Rest of World Recent Past, Current & Future Analysis for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 150: Rest of World Historic Review for RNA Analysis / Transcriptomics by Application - Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
    • TABLE 151: Rest of World 15-Year Perspective for RNA Analysis / Transcriptomics by Application - Percentage Breakdown of Value Revenues for Drug Discovery, Toxicogenomics, Clinical Diagnostics and Comparative Transcriptomics for the Years 2015, 2023 & 2030

IV. COMPETITION